Cancer Research
Papers 10000
1 page of 1,000 pages (10k results)
#1Silvia Maifrede (TU: Temple University)H-Index: 6
#2Bac Viet Le (TU: Temple University)H-Index: 4
Last. Jozef Madzo (Coriell Institute For Medical Research)H-Index: 1
view all 0 authors...
Somatic variants in TET2 and DNMT3A are founding mutations in hematological malignancies that affect the epigenetic regulation of DNA methylation. Mutations in both genes often co-occur with activating mutations in oncogenic tyrosine kinases such as FLT3ITD, BCR-ABL1, JAK2V617F, and MPLW515L, or with mutations affecting related signaling pathways such as NRASG12D and CALRdel52. Here we show that TET2 and DNMT3A mutations exert divergent roles in regulating DNA repair activities in leukemia cells...
#1Lin Yang (AHS: Alberta Health Services)H-Index: 73
#2Andria R Morielli (AHS: Alberta Health Services)
Last. Kerry S. Courneya (U of A: University of Alberta)H-Index: 133
view all 0 authors...
We systematically reviewed and synthesized evidence on the impact of physical activity/exercise on cancer treatment efficacy. We included six preclinical and seven clinical studies. Exercise significantly enhanced the efficacy of chemotherapy and tamoxifen in seven of eight rodent models in either an additive, sensitizing, or synergistic manner. In clinical studies, preliminary evidence indicates that exercise during neoadjuvant, primary, and adjuvant treatment may enhance efficacy of cancer the...
#1Chia-Chi Lin (NTU: National Taiwan University)H-Index: 32
#2Paolo Andrea Zucali (Humanitas University)H-Index: 33
Last. Monsoor Saleh (UAB: University of Alabama at Birmingham)
view all 0 authors...
Background: CD38 is implicated in noncanonical adenosine synthesis and its overexpression on tumor cells has been implicated in T-cell exhaustion and resistance to immune checkpoint blockade. Preclinical data suggest that concurrent treatment of anti-CD38 and anti-PD-1/PD-L1 antibodies substantially reduce primary tumor growth via suppressing acquired resistance to immune checkpoint blockade, and thus enhancing anti-PD-1/PD-L1 efficacy. Methods: This Phase 1/2 study (NCT03367819) enrolled pts wi...
#1Mmadili N. Ilozumba (UF: University of Florida)H-Index: 1
#2Song Yao (Roswell Park Cancer Institute)H-Index: 25
Last. Christine B. Ambrosone (Roswell Park Cancer Institute)H-Index: 86
view all 0 authors...
Background: Aberrant activation of the mammalian Target of Rapamycin (mTOR) pathway is implicated in breast carcinogenesis and outcomes. Based on protein expression data, the activation could be heterogeneous by race, body fatness, and tumor clinicopathological characteristics. To understand potential impacts of mTOR pathway signaling in breast cancer, we evaluated the association of race and clinicopathological characteristics with gene expression of select mTOR pathway genes in breast tumors. ...
#1Stephen T. Oh (WashU: Washington University in St. Louis)H-Index: 23
Last. Srdan Verstovsek (University of Texas MD Anderson Cancer Center)H-Index: 112
view all 0 authors...
Background: Anemia represents a therapeutic challenge in patients with myelofibrosis (MF). ALK2 activation is associated with elevated hepcidin, which may contribute to anemia of chronic disease and anemia due to hematologic malignancies, and is associated with increased transfusion rate and reduced overall survival. This phase 1/2, open-label, multicenter, dose-escalation/dose-expansion study will evaluate the safety and tolerability of INCB000928, a potent, highly selective, ALK2 inhibitor, as...
#1Michael Rutalira Koko (Alabama Department of Public Health)
Last. Glodi Mutamba (GSU: Georgia State University)
view all 0 authors...
Background/Purpose null Prostate cancer (PC) is the second most common and deadly cancer among men in the United States. In general, incidence rate of prostate cancer has declined while mortality rate has increased over the past 15 years. The purpose of this study is to assess the incidence and mortality rates of this cancer according to race/ethnicity from 2000-2016. null Methods null We obtained data from the Surveillance, Epidemiology and End Results (SEER) 18 program to calculate incidence a...
#1Cynthia X. Ma (WashU: Washington University in St. Louis)H-Index: 47
#2Jingqin Luo (WashU: Washington University in St. Louis)H-Index: 35
Last. Nan Lin (Harvard University)H-Index: 109
view all 0 authors...
Introduction: The irreversible pan-HER inhibitor NER showed modest single agent activity for HER2mut MBC in Part I of MutHER trial. In Part II, we hypothesized that (1) N+F would improve activity in estrogen receptor positive (ER+) HER2mut MBC due to ER-HER2 crosstalk and (2) dual HER2 blockade by adding trastuzumab at disease progression (PD) could overcome resistance. null Methods: Pts with ER+HER2mut MBC were enrolled to 2 cohorts (FUL treated or naive) to receive N+F with diarrhea prophylaxi...
#1Danny R. Welch (KU: University of Kansas)H-Index: 80
The complex interplay between tumor cells and the multiple microenvironments with which they interact during metastasis provides numerous potential targets for therapeutic intervention. Since metastasis is the primary cause of cancer morbidity and mortality, critical evaluation and prioritization of those targets represents the first step in developing treatments specifically targeting metastases. I will focus on the four features of metastatic cells that distinguish them from malignant cancer c...
#1Anand Krishnan (U of S: University of Saskatchewan)H-Index: 13
#2Shubham Dwivedi (U of S: University of Saskatchewan)H-Index: 8
Last. Tauqeer Iftikhar (U of S: University of Saskatchewan)
view all 0 authors...
Prostate cancer is the leading cancer diagnosed among men worldwide. The prostate cancer-associated mortality is due to the development of aggressive neuroendocrine prostate cancer (NEPC). Unfortunately, there is no effective treatment available for NEPC at present. This is due to the lack of proper understanding of the molecular switch that triggers neuroendocrine changes in prostate adenocarcinoma cells. Recent research demonstrated that peripheral nerves promote prostate cancer progression an...
#1Shiqi LiH-Index: 3
#2Lei Gao (Third Military Medical University)H-Index: 7
Last. Duanpeng WangH-Index: 2
view all 0 authors...
Introduction: null T-ALL represents an area of high unmet medical need. Once relapsed, patients have limited treatment options. We first reported data from a single-arm, open-label, multi-center, investigator-initiated study in adults with r/r T-ALL (ChiCTR1900025311) treated with TruUCAR™ GC027, an off-the-shelf CAR-T product at AACR 2020. Here we report long term follow-up results and preliminary results of additional patients treated. null Methods: null Between July 2019 to Feb 2021, a total ...
Top fields of study
Molecular biology
Cancer research
Breast cancer